Acino will acquire Cephalon’s combined Middle East and African business for a total consideration of approximately EUR 80 million.
Acino will pay EUR 60 million in cash and EUR 20 million through the issuance of shares from authorized capital (calculated at the average share price on the day prior to the closing of the transaction).
Acino expects the acquisition to be immediately accretive.
The business to be acquired, which includes Cephalon and Mepha brands, is expected to generate sales of close to EUR 100 million in 2011.
The well established product portfolio comprises leading brands including the analgesic Olfen (diclofenac), the antispasmotic Spasfon (phloroglucinol/trimethylphloroglucinol), the gastrointestinal drug Gasec (omeprazole) and the antibiotic Mesporin (ceftriaxone).
Through this transaction, Acino makes a quantum leap towards establishing its own market presence in emerging markets. Peter Burema, Acino’s CEO, stated; “This is a game-changing acquisition for our company and underpins our commitment to building Acino’s own market presence in up-and-coming economies. The acquired products ideally complement our own portfolio. The Mepha legacy, built on its Swiss heritage, will live on through this acquisition by Acino, also headquartered in Switzerland and committed to the same high quality standards”.
See the full press release and details at Current Agreements (subscription required)